Detailed Mechanism Funding and Narrative

Years of mechanism: 2018 2019 2020

Details for Mechanism ID: 70077
Country/Region: Ethiopia
Year: 2018
Main Partner: Amhara Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $4,900,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $614,250
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $226,764
Care: Pediatric Care and Support (PDCS) $236,250
Laboratory Infrastructure (HLAB) $75,000
Strategic Information (HVSI) $100,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $652,631
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,514,001
Treatment: Pediatric Treatment (PDTX) $481,104
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 30
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 32
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 41
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 88
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 211
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 39
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 5
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 178
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 259
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 2
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 75
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 179
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 18
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 27
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 8
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 5
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 418
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 492
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 744
GEND_GBV Number of people receiving post-GBV care 2019 1,238
HTS_SELF 2019 1,231
HTS_SELF 15-19, Female, Directly-Assisted 2019 69
HTS_SELF 15-19, Male, Directly-Assisted 2019 63
HTS_SELF 20-24, Female, Directly-Assisted 2019 116
HTS_SELF 20-24, Male, Directly-Assisted 2019 108
HTS_SELF 25-29, Female, Directly-Assisted 2019 123
HTS_SELF 25-29, Male, Directly-Assisted 2019 139
HTS_SELF 30-34, Female, Directly-Assisted 2019 101
HTS_SELF 30-34, Male, Directly-Assisted 2019 87
HTS_SELF 35-39, Female, Directly-Assisted 2019 101
HTS_SELF 35-39, Male, Directly-Assisted 2019 90
HTS_SELF 40-49, Female, Directly-Assisted 2019 79
HTS_SELF 40-49, Male, Directly-Assisted 2019 106
HTS_SELF 50+, Female, Directly-Assisted 2019 26
HTS_SELF 50+, Male, Directly-Assisted 2019 25
HTS_SELF Directly-Assisted 2019 1,141
HTS_SELF FSW, Directly-Assisted 2019 599
HTS_SELF Unassisted 2019 90
HTS_TST <5, Unknown Sex, Negative 2019 927
HTS_TST 15-19, Female, Negative 2019 111
HTS_TST 15-19, Male, Negative 2019 66
HTS_TST 20-24, Female, Negative 2019 390
HTS_TST 20-24, Male, Negative 2019 249
HTS_TST 25-29, Female, Negative 2019 2,506
HTS_TST 25-29, Female, Negative 2019 552
HTS_TST 25-29, Female, Negative 2019 729
HTS_TST 25-29, Female, Negative 2019 11,020
HTS_TST 25-29, Male, Negative 2019 2,837
HTS_TST 25-29, Male, Negative 2019 460
HTS_TST 25-29, Male, Negative 2019 728
HTS_TST 25-29, Male, Negative 2019 5,896
HTS_TST 30-34, Female, Negative 2019 2,065
HTS_TST 30-34, Female, Negative 2019 426
HTS_TST 30-34, Female, Negative 2019 720
HTS_TST 30-34, Female, Negative 2019 745
HTS_TST 30-34, Male, Negative 2019 1,771
HTS_TST 30-34, Male, Negative 2019 511
HTS_TST 30-34, Male, Negative 2019 723
HTS_TST 30-34, Male, Negative 2019 2,931
HTS_TST 35-39, Female, Negative 2019 2,065
HTS_TST 35-39, Female, Negative 2019 424
HTS_TST 35-39, Female, Negative 2019 368
HTS_TST 35-39, Female, Negative 2019 4,390
HTS_TST 35-39, Male, Negative 2019 1,771
HTS_TST 35-39, Male, Negative 2019 510
HTS_TST 35-39, Male, Negative 2019 361
HTS_TST 35-39, Male, Negative 2019 3,681
HTS_TST 40-49, Female, Negative 2019 2,949
HTS_TST 40-49, Female, Negative 2019 1,482
HTS_TST 40-49, Female, Negative 2019 469
HTS_TST 40-49, Female, Negative 2019 361
HTS_TST 40-49, Male, Negative 2019 3,686
HTS_TST 40-49, Male, Negative 2019 2,185
HTS_TST 40-49, Male, Negative 2019 587
HTS_TST 40-49, Male, Negative 2019 353
HTS_TST 50+, Female, Negative 2019 98
HTS_TST 50+, Male, Negative 2019 98
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 109,774
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 2,917
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 2,738
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 3,161
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 736
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 737
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 2,195
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,476
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 2,949
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 2,950
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 103
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 74
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 59
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1,614
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 1,316
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 2,401
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 2,220
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 509
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 507
HTS_TST Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 205
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 142
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 214
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 216
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 354
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 289
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 726
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 645
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 147
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 148
HTS_TST_POS <5, Unknown Sex, Positive 2019 20
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 15-19, Male, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 11
HTS_TST_POS 20-24, Male, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 47
HTS_TST_POS 25-29, Female, Positive 2019 19
HTS_TST_POS 25-29, Female, Positive 2019 66
HTS_TST_POS 25-29, Female, Positive 2019 872
HTS_TST_POS 25-29, Male, Positive 2019 54
HTS_TST_POS 25-29, Male, Positive 2019 11
HTS_TST_POS 25-29, Male, Positive 2019 65
HTS_TST_POS 25-29, Male, Positive 2019 523
HTS_TST_POS 30-34, Female, Positive 2019 38
HTS_TST_POS 30-34, Female, Positive 2019 11
HTS_TST_POS 30-34, Female, Positive 2019 56
HTS_TST_POS 30-34, Female, Positive 2019 93
HTS_TST_POS 30-34, Male, Positive 2019 33
HTS_TST_POS 30-34, Male, Positive 2019 16
HTS_TST_POS 30-34, Male, Positive 2019 51
HTS_TST_POS 30-34, Male, Positive 2019 237
HTS_TST_POS 35-39, Female, Positive 2019 40
HTS_TST_POS 35-39, Female, Positive 2019 13
HTS_TST_POS 35-39, Female, Positive 2019 19
HTS_TST_POS 35-39, Female, Positive 2019 362
HTS_TST_POS 35-39, Male, Positive 2019 34
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 35-39, Male, Positive 2019 312
HTS_TST_POS 40-49, Female, Positive 2019 248
HTS_TST_POS 40-49, Female, Positive 2019 27
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Female, Positive 2019 13
HTS_TST_POS 40-49, Male, Positive 2019 316
HTS_TST_POS 40-49, Male, Positive 2019 40
HTS_TST_POS 40-49, Male, Positive 2019 19
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 50+, Female, Positive 2019 2
HTS_TST_POS 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 371
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 387
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 395
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 59
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 65
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 175
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 124
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 248
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 248
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 48
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 78
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 59
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 5
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 6,453
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 6,453
PMTCT_ART Already on ART at beginning of current pregnancy 2019 2,801
PMTCT_ART New on ART 2019 1,491
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 4,292
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 2,621
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 657
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 3,278
PMTCT_EID Sum of Infant Age disaggregates 2019 3,278
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 10
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 321
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 12
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 317
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 659
TB_PREV By Age/Sex (Numerator): <15, Female 2019 140
TB_PREV By Age/Sex (Numerator): <15, Female 2019 1,697
TB_PREV By Age/Sex (Numerator): <15, Male 2019 140
TB_PREV By Age/Sex (Numerator): <15, Male 2019 1,695
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 1,250
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 15,323
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,248
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 15,315
TB_PREV IPT, Life-long ART, Already, Positive 2019 2,322
TB_PREV IPT, Life-long ART, Already, Positive 2019 25,077
TB_PREV IPT, Life-long ART, New, Positive 2019 475
TB_PREV IPT, Life-long ART, New, Positive 2019 4,934
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 34,034
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 2,797
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 34,832
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,899
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,743
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 93
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 1,742
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 93
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 15,733
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 814
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 15,718
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 815
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 1,507
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 24,722
TB_PREV_den IPT, Life-long ART, New, Positive 2019 308
TB_PREV_den IPT, Life-long ART, New, Positive 2019 5,053
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 459
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 3,836
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 921
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 5,242
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 10,510
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 11,136
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 496
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 4,214
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 964
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 5,741
TX_CURR 25-29, Female, Positive 2019 4,779
TX_CURR 25-29, Female, Positive 2019 36
TX_CURR 25-29, Male, Positive 2019 2,103
TX_CURR 25-29, Male, Positive 2019 15
TX_CURR 30-34, Female, Positive 2019 13,711
TX_CURR 30-34, Female, Positive 2019 104
TX_CURR 30-34, Male, Positive 2019 3,988
TX_CURR 30-34, Male, Positive 2019 30
TX_CURR 35-39, Female, Positive 2019 12,672
TX_CURR 35-39, Female, Positive 2019 95
TX_CURR 35-39, Male, Positive 2019 4,807
TX_CURR 35-39, Male, Positive 2019 35
TX_CURR 40-49, Female, Positive 2019 29,128
TX_CURR 40-49, Female, Positive 2019 221
TX_CURR 40-49, Male, Positive 2019 20,630
TX_CURR 40-49, Male, Positive 2019 157
TX_CURR Age/Sex: <1 2019 216
TX_CURR Age/Sex: <1 2019 11
TX_CURR Age/Sex: <1-9 2019 1,085
TX_CURR Age/Sex: 1-9 2019 4
TX_CURR Age/Sex: 10-14 Female 2019 3,353
TX_CURR Age/Sex: 10-14 Female 2019 24
TX_CURR Age/Sex: 10-14 Male 2019 3,642
TX_CURR Age/Sex: 10-14 Male 2019 29
TX_CURR Age/Sex: 15-19 Female 2019 5,151
TX_CURR Age/Sex: 15-19 Female 2019 39
TX_CURR Age/Sex: 15-19 Male 2019 4,148
TX_CURR Age/Sex: 15-19 Male 2019 31
TX_CURR Age/Sex: 20-24 Female 2019 6,291
TX_CURR Age/Sex: 20-24 Female 2019 48
TX_CURR Age/Sex: 20-24 Male 2019 4,289
TX_CURR Age/Sex: 20-24 Male 2019 32
TX_CURR Age/Sex: 50+ Female 2019 19,723
TX_CURR Age/Sex: 50+ Female 2019 149
TX_CURR Age/Sex: 50+ Male 2019 11,741
TX_CURR Age/Sex: 50+ Male 2019 88
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 151,486
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 1,304
TX_CURR Sum of age/sex disaggregates 2019 9,299
TX_CURR Sum of Age/Sex disaggregations 2019 70
TX_NEW 25-29, Female, Positive 2019 265
TX_NEW 25-29, Female, Positive 2019 17
TX_NEW 25-29, Male, Positive 2019 136
TX_NEW 25-29, Male, Positive 2019 10
TX_NEW 30-34, Female, Positive 2019 803
TX_NEW 30-34, Female, Positive 2019 46
TX_NEW 30-34, Male, Positive 2019 274
TX_NEW 30-34, Male, Positive 2019 20
TX_NEW 35-39, Female, Positive 2019 747
TX_NEW 35-39, Female, Positive 2019 45
TX_NEW 35-39, Male, Positive 2019 350
TX_NEW 35-39, Male, Positive 2019 21
TX_NEW 40-49, Female, Positive 2019 1,657
TX_NEW 40-49, Female, Positive 2019 103
TX_NEW 40-49, Male, Positive 2019 1,482
TX_NEW 40-49, Male, Positive 2019 90
TX_NEW Breastfeeding status 2019 37
TX_NEW By Age/Sex: <1 2019 29
TX_NEW By Age/Sex: <1 2019 9
TX_NEW By Age/Sex: 1-9 2019 202
TX_NEW By Age/Sex: 1-9 2019 49
TX_NEW By Age/Sex: 10-14 Female 2019 433
TX_NEW By Age/Sex: 10-14 Female 2019 84
TX_NEW By Age/Sex: 10-14 Male 2019 206
TX_NEW By Age/Sex: 10-14 Male 2019 47
TX_NEW By Age/Sex: 15-19 Female 2019 129
TX_NEW By Age/Sex: 15-19 Female 2019 10
TX_NEW By Age/Sex: 15-19 Male 2019 16
TX_NEW By Age/Sex: 20-24 Female 2019 34
TX_NEW By Age/Sex: 20-24 Female 2019 1
TX_NEW By Age/Sex: 20-24 Male 2019 131
TX_NEW By Age/Sex: 20-24 Male 2019 10
TX_NEW By Age/Sex: 50+ Female 2019 633
TX_NEW By Age/Sex: 50+ Female 2019 40
TX_NEW By Age/Sex: 50+ Male 2019 425
TX_NEW By Age/Sex: 50+ Male 2019 28
TX_NEW FSW 2019 39
TX_NEW FSW 2019 1
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 8,029
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 648
TX_NEW Pregnancy status 2019 301
TX_NEW Pregnancy status 2019 40
TX_NEW Sum of Age/Sex disaggregates 2019 2,007
TX_NEW Sum of Age/Sex disaggregates 2019 220
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 131,473
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,625
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 666
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 2,891
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 661
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 63,398
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 11,157
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 42,746
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 7,518
TX_PVLS_den Denominator: Indication: Routine 2019 93,016
TX_PVLS_den Denominator: Indication: Targeted 2019 8,399
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 368
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 383
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8,612
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4,696
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 14,075
TX_RET Numerator by Status: Breastfeeding 2019 70
TX_RET Numerator by Status: Pregnant 2019 90
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 15,248
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 414
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 427
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 9,322
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 5,086
TX_RET_den Denominator by Status: Breastfeeding 2019 78
TX_RET_den Denominator by Status: Pregnant 2019 97
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 115,601
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 1,430
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 50
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 48
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 1,040
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 1,043
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 3,407
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 3,530
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 53,171
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 55,503
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 8,466
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 3,638
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 1,700
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 9,657
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 98,361
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 10,306
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 5,784
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 1,205
Cross Cutting Budget Categories and Known Amounts Total: $2,500,500
Gender: Gender Based Violence (GBV) $92,500
GBV Prevention
Water $63,000
Human Resources for Health $2,300,000
Food and Nutrition: Policy, Tools, and Service Delivery $20,000
Adolescent Girls and Young Women (AGYW) $25,000